Solid Dispersions for Oral Delivery: Materials, Technologies, Characterization, and Translation

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 25 March 2027 | Viewed by 1456

Special Issue Editors


E-Mail Website
Guest Editor
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania
Interests: pharmaceutical technology; drug design; quality by design

E-Mail Website
Guest Editor
Department of Preclinical Medicine, Lucian Blaga University of Sibiu, Sibiu, Romania
Interests: biopharmaceutics; pharmacokinetics; pharmaceutical technology

E-Mail Website
Guest Editor
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 2A Lucian Blaga Street, 550169 Sibiu, Romania
Interests: analytical method development and validation; quality control of health products; drug delivery; cosmetics; nutricosmeticsș nutraceuticals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the design, preparation, characterization, and translational development of solid dispersion systems for improving the oral delivery of poorly soluble active pharmaceutical ingredients. We welcome contributions on amorphous and crystalline solid dispersions, supersaturating drug delivery systems, and related formulation strategies intended to enhance solubility, dissolution, stability, permeability, and oral bioavailability. Topics of interest include carrier and excipient selection, drug–polymer miscibility, precipitation inhibition, advanced manufacturing technologies such as hot-melt extrusion, spray drying, electrospinning, freeze-drying, and solvent-based methods, as well as solid-state characterization and stability assessment. Studies addressing biorelevant dissolution, in vitro–in vivo correlations, pharmacokinetics, quality-by-design, scale-up, manufacturability, and regulatory considerations are also encouraged. Original research articles, reviews, and short communications that combine mechanistic insight with practical formulation development are particularly welcome.

Dr. Andrei Cătălin Muntean
Dr. Andreea Loredana Vonica-Tincu
Dr. Luca-Liviu Rus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • solid dispersions
  • amorphous solid dispersions
  • supersaturating drug delivery systems
  • poorly soluble drugs
  • BCS class II and IV drugs
  • solubility enhancement
  • dissolution enhancement
  • oral bioavailability
  • oral absorption
  • drug–polymer miscibility
  • precipitation inhibition
  • polymer carriers
  • hot-melt extrusion
  • spray drying
  • electrospinning
  • freeze-drying
  • solid-state characterization
  • physical stability
  • biorelevant dissolution
  • IVIVC
  • pharmacokinetics
  • quality by design
  • scale-up
  • regulatory science

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1520 KB  
Article
Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate
by Ryo Ohashi, Shuichi Otake, Tatsuhiko Murata, Ryosuke Watari, Shinpei Yoshida, Mikiko Kitade, Daisuke Kondo and Go Kimura
Pharmaceutics 2025, 17(12), 1627; https://doi.org/10.3390/pharmaceutics17121627 - 18 Dec 2025
Viewed by 932
Abstract
Background/Objectives: S-892216 is a poorly water-soluble drug developed as a novel oral treatment for COVID-19, although its oral absorption is low. For Phase 1 (Ph1) studies and commercial use, both oral solution and solid dispersion technologies are evaluated to enhance drug solubility. [...] Read more.
Background/Objectives: S-892216 is a poorly water-soluble drug developed as a novel oral treatment for COVID-19, although its oral absorption is low. For Phase 1 (Ph1) studies and commercial use, both oral solution and solid dispersion technologies are evaluated to enhance drug solubility. Methods: The solubility enhancement technology was selected by considering physicochemical factors such as stability and oral absorption, along with patient and customer acceptability. Results: Pharmacokinetics study in rats revealed that both the polyethylene glycol 400 oral solution and polyvinylpyrrolidone-vinyl acetate (PVPVA) amorphous solid dispersion powder suspension showed almost 100% oral bioavailability. Therefore, they can be proposed as clinical formulations for Ph1 studies. PVPVA solid dispersion tablets were developed as a to-be-marketed formulation showed higher bioavailability in dogs than the anhydrous crystal formulation. Additionally, the stability of the developed solid dispersion tablet was acceptable. Conclusions: This study demonstrates that multiple solubility enhancement technologies can be adopted for S-892216 development, and amorphous solid dispersion technology was selected for commercialization. Full article
Show Figures

Figure 1

Back to TopTop